• Intervacc's stock is up 3.2% today, trading at €0.09, following recent positive company developments.
  • The company submitted a Type II variation application to the European Medicines Agency (EMA) on July 30, 2026, seeking to extend the duration of immunity for its Strangvac horse vaccine to 12 months.
  • This follows the first export of Strangvac to New Zealand under a Special Circumstances Permit, announced on July 29, 2026, marking an expansion into a new market.